Study of Atorvastatin Dose Dependent Reduction of Proteinuria

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Age of 18 and over

• Stage 3 or 4 chronic kidney disease (modified MDRD)

• proteinuria of > 1g/d on ACEi and/or ARB, or proteinuria of > 1g/d with intolerance or contraindication to ACEi and/or ARB

• blood pressure < 130/80 mmHg or < 140/90 mmHg in patients with five or more antihypertensive drugs

• stable renal function

Exclusion Criteria:

• rapid progression of renal failure

• immunosuppressive therapy within the past 3 months

• need a renal replacement therapy within 8 months

• definite history of chronic liver disease, or abnormal liver function

• evidence of active inflammatory muscle disease

• definite previous adverse reaction to a statin

• concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin)

• child bearing potential

• known to be poorly compliant with clinic visits or prescribed medication